Trial Profile
Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2022
Price :
$35
*
At a glance
- Drugs Rogaratinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SAKK 19/18
- 01 Oct 2022 Primary endpoint (Progression-free survival (PFS) at 6 months) has not been met, according to Results published in the Lung Cancer.
- 01 Oct 2022 Results assessing clinical activity of rogaratinib in patients with advanced SQCLC overexpressing FGFR1-3 mRNA, published in the Lung Cancer.
- 20 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.